Your browser doesn't support javascript.
loading
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
Warner, Nathaniel C; Bartelt, Luther A; Lachiewicz, Anne M; Tompkins, Kathleen M; Miller, Melissa B; Alby, Kevin; Jones, Melissa B; Carr, Amy L; Alexander, Jose; Gainey, Andrew B; Daniels, Robert; Burch, Anna-Kathryn; Brown, David E; Brownstein, Michael J; Cheema, Faiqa; Linder, Kristin E; Shields, Ryan K; Longworth, Sarah; van Duin, David.
Affiliation
  • Warner NC; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Bartelt LA; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Lachiewicz AM; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Tompkins KM; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Miller MB; Clinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
  • Alby K; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Jones MB; Clinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
  • Carr AL; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Alexander J; Clinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
  • Gainey AB; Department of Pharmacy, Advent Health Orlando, Orlando, Florida, USA.
  • Daniels R; Department of Microbiology/Virology/Immunology, Advent Health, Orlando, Florida, USA.
  • Burch AK; Prisma Health Children's Hospital-Midlands, Columbia, South Carolina, USA.
  • Brown DE; Prisma Health Children's Hospital-Midlands, Columbia, South Carolina, USA.
  • Brownstein MJ; Prisma Health Children's Hospital-Midlands, Columbia, South Carolina, USA.
  • Cheema F; Department of Pediatrics, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
  • Linder KE; Prisma Health Children's Hospital-Midlands, Columbia, South Carolina, USA.
  • Shields RK; Department of Pediatrics, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
  • Longworth S; Adaptive Phage Therapeutics, Gaithersburg, Maryland, USA.
  • van Duin D; Division of Infectious Diseases, University of Connecticut, Farmington, Connecticut, USA.
Clin Infect Dis ; 73(7): e1754-e1757, 2021 10 05.
Article in En | MEDLINE | ID: mdl-33313656
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gram-Negative Bacterial Infections / Cystic Fibrosis / Achromobacter denitrificans Limits: Adult / Child / Humans Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gram-Negative Bacterial Infections / Cystic Fibrosis / Achromobacter denitrificans Limits: Adult / Child / Humans Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States